Assembly Biosciences

Assembly Biosciences P/CF

The P/CF (Price-to-Cash-Flow Ratio) of Assembly Biosciences (ASMB) as of Oct 17, 2026 is -10.26. In the previous year, P/CF (Price-to-Cash-Flow Ratio) was -8.25 — a change of 24.39% (lower).

P/CF

-10.26

YoY

24.39%

Last updated:

P/CF (Price-to-Cash-Flow Ratio) of Assembly Biosciences is 2025 -10.26 . P/CF (Price-to-Cash-Flow Ratio) of Assembly Biosciences was 2024 -8.25 . It decreases by 24.39% lower compared to the previous year.

The Assembly Biosciences P/CF history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

P/CF
Date
P/CF
Jan 1, 2018
-6.49 USD
Jan 1, 2019
-5.02 USD
Jan 1, 2020
-6.70 USD
Jan 1, 2021
-4.52 USD
Jan 1, 2022
-4.99 USD
Jan 1, 2023
18.54 USD
Jan 1, 2024
-8.25 USD
Jan 1, 2025
-10.26 USD
The Assembly Biosciences P/CF history
YEARP/CFYoY
-10.26+24.39%
-8.25-144.49%
18.54-471.38%
-4.99+10.58%
-4.52-32.59%
-6.70+33.53%
-5.02-22.73%
-6.49-102.86%
226.70-1,975.28%
-12.09-46.40%
-22.55-19.92%
-28.16—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Assembly Biosciences Stock analysis

What does Assembly Biosciences do? Assembly Biosciences Inc is a biotechnology company based in South San Francisco, United States, specializing in the development of therapeutics for infectious diseases. The firm focuses on two primary platform programs: oral therapeutics targeting chronic hepatitis B virus (HBV) infection and oral synthetic live therapeutics designed to restore health to a dysbiotic microbiome. Its HBV program utilizes core protein allosteric modulators (CpAMs), small molecules that directly target the HBV core protein. The microbiome initiative features an integrated platform including strain identification, isolation under good manufacturing practice conditions, and the GEMICEL delivery system for targeted oral administration to the lower gastrointestinal tract. The company went public in December 2010 and employs staff dedicated to these innovative medical solutions. Assembly Biosciences is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Assembly Biosciences stock

P/CF (Price-to-Cash-Flow Ratio) of Assembly Biosciences is -10.26 in 2025.

P/CF (Price-to-Cash-Flow Ratio) of Assembly Biosciences changed from -8.25 to -10.26, representing a 24.39% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of P/CF (Price-to-Cash-Flow Ratio) Assembly Biosciences since 2006 – with annual values, charts, and detailed analysis.

The Price-to-Cash-Flow ratio measures the stock price relative to operating cash flow per share. Unlike P/E, it is harder to manipulate as cash flow is less subject to accounting adjustments.

P/CF = Stock Price / Operating Cash Flow per Share

To evaluate P/CF (Price-to-Cash-Flow Ratio)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for P/CF (Price-to-Cash-Flow Ratio).

A 'good' varies by industry and company stage. On Eulerpool, you can compare P/CF (Price-to-Cash-Flow Ratio)'s Assembly Biosciences with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Valuation — Assembly Biosciences

P/EP/SEV/EBITP/BP/CFP/FCFPEGEV/RevenueEV/EBITDAEV/FCFEarnings YieldFCF YieldMarket capitalizationEnterprise ValueForward P/EP/TBVShareholder YieldBuyback YieldDiv.-Adj. PEGEV/OCF

All Key Metrics — Assembly Biosciences